Back to Screener

Healthcare

Ascletis Pharma Inc.(ASCLF)

Live Price

Offline

$1.35

+0.00% today

Window Change

-19.16%

Window

May 29, 2026 โ†’ Jun 24, 2026

Market Cap
$15.37B
Revenue Growth
+54.0%
EPS Growth
-20.0%
Dividend Yield
0.0%
Sparse coverage

Historical coverage is still filling in

This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.

Coverage: 19 bars ยท May 29, 2026 โ†’ Jun 24, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Ascletis Pharma Inc. (ASCLF) is a Healthcare stock with a market cap of $15.37B. The stock last traded around $1.35 and down 19.2% across the available one-year price window (May 29, 2026 โ†’ Jun 24, 2026). Baseline metrics include revenue growth of +54.0%, EPS growth of -20.0%, a dividend yield of 0.0%. What stands out right now is revenue +54.0%, EPS -20.0%, free cash flow +3.7% with operating margin -23797.7% and ROIC -24.6%. Valuation already assumes a fairly strong business story at price/sales 7636.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ASCLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

ASCLF vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

ASCLF

โ€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

ASCLF Max Drawdown

-20.96%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for ASCLF and SPY.

Calendar-year return history is still loading or unavailable.

Earnings Reports

๐Ÿ“… Last reportedMar 13, 2026Q1
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”Report
Q1
Mar 13, 26
โœ“
1.59
Est 1.51
+5.3%
โ€”
Est โ€”
โ€”
Mar 13
Q1
Feb 6, 26
โœ“
6.15
Est 3.18
+93.4%
โ€”
Est โ€”
โ€”
Feb 6
Q1
Jan 23, 26
โœ“
1.87
Est 1.61
+16.1%
โ€”
Est โ€”
โ€”
Jan 23
No upcoming earnings in the next 90 days

Next Step

Connect reports to catalysts

Earnings pages get much more useful when they are tied back to upcoming dates, expectations, and peer setups.